Bristol-Myers Squibb and Five Prime Therapeutics announce exclusive clinical collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb's investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R).
Novartis Foundation symposium showcases sustainable healthcare interventions
- Details
- Category: Novartis
Today, the Novartis Foundation, formerly named the Novartis Foundation for Sustainable Development, convenes its annual symposium. This year's topic - "Sustainable healthcare interventions: from blueprint to lasting impact" - brings together philanthropists, local partners and innovators to explore the journey from idea generation and pilot projects to the realization of scalable and sustainable healthcare systems that improve outcomes for patients in low- and middle-income countries.
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
- Details
- Category: Boehringer Ingelheim
Two new real-world data analyses presented at the American Heart Association's Scientific Sessions 2014 independently demonstrate that routine treatment with Pradaxa® (dabigatran etexilate) was associated with fewer major bleeds and strokes compared to warfarin.(1,2)
Novo Nordisk second best in the world at providing access to medicine
- Details
- Category: Novo Nordisk
Today, it was announced that Novo Nordisk ranks second on the 2014 Access to Medicine Index, climbing four places since the 2012 Index. Novo Nordisk's ranking is a reflection of the company's inclusion of access to medicine within its core business, including equitable pricing strategies, local capability building and integrating philanthropy with business activities.
Bristol-Myers Squibb to construct a new large-scale biologics manufacturing facility in Ireland
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company's growing biologics portfolio.
AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor (BRILINTA®) in rare emergency situations such as urgent surgery, or in the event of major bleeding.
Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it will invest 450 million Swiss Francs over the next three years to establish a new diagnostic manufacturing facility at the Suzhou Industrial Park, in Suzhou, China. The new manufacturing site sets out to address the continuously growing demand for diagnostic tests in China and the Asia Pacific region.
More Pharma News ...
- Bayer operationally strong - strategic focus on Life Science businesses
- AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
- Bristol-Myers Squibb enters into agreement that provides an exclusive option to acquire F-star Alpha Ltd. and its novel HER2-targeted therapy
- AstraZeneca strengthens partnership with the University of Cambridge
- Roche delivers solid sales growth for the first nine months of 2014
- Novo Nordisk second best science employer in the world
- Bayer supports World Thrombosis Day as founding global partner